Common, Rare and Somatic Genetic Drivers Together Double 5‑Year Atrial Fibrillation Risk: Toward an Integrated Genomic Model (IGM‑AF)
Posted inCardiology news Pathology & Lab Medicine

Common, Rare and Somatic Genetic Drivers Together Double 5‑Year Atrial Fibrillation Risk: Toward an Integrated Genomic Model (IGM‑AF)

A UK Biobank whole‑genome study finds polygenic, rare monogenic, and somatic (CHIP) variants each independently associate with incident atrial fibrillation (AF); combined genomic profiling plus clinical risk (CHARGE‑AF) improves discrimination (C=0.80) and reclassification.
Preoperative Clues That Predict Who Will Receive Adjuvant Therapy After Surgery for Oral Cavity Cancer
Posted innews Oncology Otorhinolaryngology Pathology & Lab Medicine

Preoperative Clues That Predict Who Will Receive Adjuvant Therapy After Surgery for Oral Cavity Cancer

In a multicenter cohort of 3,980 oral cavity squamous cell carcinoma patients, preoperative clinical and tumor features—including age, comorbidity, tumor subsite, size, clinical stage, and biopsy grade—predicted receipt and intensity of adjuvant therapy, with a predictive model AUC of 0.84.
ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: DYNAMIC-III Validates Prognosis but Questions Intensification
Posted inGastroenterology news Oncology Pathology & Lab Medicine

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: DYNAMIC-III Validates Prognosis but Questions Intensification

The randomized phase 2/3 DYNAMIC-III trial shows that postoperative circulating tumor DNA (ctDNA) strongly stratifies recurrence risk in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with outcomes close to standard care; escalation for ctDNA-positive disease did not improve recurrence-free survival.
ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial
Posted innews Oncology Pathology & Lab Medicine

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial

The DYNAMIC-III trial validates circulating tumor DNA (ctDNA) as a strong prognostic marker in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with near-standard outcomes, but escalation for ctDNA-positive patients failed to improve recurrence-free survival.
Indole-3-Propionic Acid Bridges Gut Dysfunction and Diabetic Retinopathy — A Biomarker and Therapeutic Avenue
Posted inDiabetes & Endocrinology news Ophthalmology Pathology & Lab Medicine

Indole-3-Propionic Acid Bridges Gut Dysfunction and Diabetic Retinopathy — A Biomarker and Therapeutic Avenue

A Gut 2025 study identifies microbially produced indole-3-propionic acid (IPA) as a protective metabolite linking restored intestinal tryptophan handling to prevention of diabetic retinopathy in mice and associates low serum IPA with retinopathy in people with type 2 diabetes.
Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings
Posted inGastroenterology news Pathology & Lab Medicine

Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings

An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑naïve patients and outperformed available clinical decision support tools.
Evaluating Self-Collected Urine and Vaginal Samples for HPV Genotyping in Cervical Cancer Screening Among Japanese Women
Posted inInfectious Diseases news Pathology & Lab Medicine

Evaluating Self-Collected Urine and Vaginal Samples for HPV Genotyping in Cervical Cancer Screening Among Japanese Women

This study assesses the feasibility and performance of using self-collected urine and vaginal samples with the BD Onclarity® HPV assay for cervical cancer screening in Japanese women with abnormal cytology, highlighting concordance and sensitivity metrics compared to clinician-collected cervical samples.
Impact of Epstein-Barr Virus Serology on Oral HPV Infection Dynamics in Early Childhood: Insights from the Finnish Family HPV Cohort
Posted inDentistry Infectious Diseases news Pathology & Lab Medicine Pediatrics

Impact of Epstein-Barr Virus Serology on Oral HPV Infection Dynamics in Early Childhood: Insights from the Finnish Family HPV Cohort

This study explores how early Epstein-Barr virus (EBV) infection and immune responses influence oral human papillomavirus (HPV) infections in children, revealing the interplay between EBV serology, paternal education, and oral HPV acquisition and clearance during the first three years of life.
Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives
Posted inAI Oncology Pathology & Lab Medicine Specialties

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives

AI-detected tumor-infiltrating lymphocytes on routine histology independently predict response and survival in advanced melanoma treated with anti-PD-1 therapies, outperforming manual scoring and offering an accessible biomarker for immune checkpoint inhibitor outcomes.
Standardizing Pathological Response Reporting After Neoadjuvant Therapy in Kidney Cancer: New International Guidelines
Posted inOncology Pathology & Lab Medicine Specialties

Standardizing Pathological Response Reporting After Neoadjuvant Therapy in Kidney Cancer: New International Guidelines

International experts issue consensus guidelines for sampling and reporting pathological response to neoadjuvant therapy in renal cell carcinoma, recommending standardized specimen sampling and quantification of residual viable tumor to enable reliable trial endpoints and future clinical use.